Evolus, Inc.'s (NASDAQ:EOLS) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 16% Over Last Week

Key Insights Given the large stake in the stock by institutions, Evolus' stock price might be vulnerable to their trading decisions 52% of the business is held by the top 10 shareholders Insiders

Simply Wall StMay 5 09:50 ET

The 15% Return This Week Takes Evolus' (NASDAQ:EOLS) Shareholders One-year Gains to 59%

Yahoo FinanceMay 3 11:05 ET

Evolus to Report First Quarter Financial Results on May 7, 2024

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May

BusinesswireApr 23 16:30 ET

Evolus Announces Publication Of Safety and Duration Data From Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau

The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of moderate to severe glabellar lines presented at the 2023 ASDS A

BenzingaApr 17 16:13 ET

AbbVie Working With FDA After Reports of Fake Botox Versions

Seeking AlphaApr 16 10:47 ET

Evolus Insiders Sell US$3.0m Of Stock, Possibly Signalling Caution

Over the past year, many Evolus, Inc. (NASDAQ:EOLS) insiders sold a significant stake in the company which may have piqued investors' interest. When analyzing insider transactions, it is usually mor

Simply Wall StApr 14 08:53 ET